Literature DB >> 23794601

Interactions between tenofovir and nevirapine in CD4+ T cells and monocyte-derived macrophages restrict their intracellular accumulation.

N J Liptrott1, P Curley, D Moss, D J Back, S H Khoo, A Owen.   

Abstract

OBJECTIVES: There is no pharmacokinetic interaction between tenofovir and nevirapine, but a higher emergence rate of resistance mutations has been reported when these drugs are coadministered. We sought to examine if there is a potential intracellular interaction that may account for the emergence of resistant virus.
METHODS: Primary CD4+ and CD14+ cells were isolated from healthy volunteer blood. Monocyte-derived macrophages were differentiated from CD14+ cells. Accumulation of radiolabelled tenofovir and nevirapine was then assessed in these cells.
RESULTS: We show here that tenofovir and nevirapine immune cell intracellular concentrations are lower when coincubated in CD4+ cells and monocyte-derived macrophages, but not in CD14+ cells.
CONCLUSIONS: These data indicate a potential intracellular drug-drug interaction between these drugs that warrants further investigation.

Entities:  

Keywords:  HIV; drug–drug interactions; influx drug transporters

Mesh:

Substances:

Year:  2013        PMID: 23794601      PMCID: PMC3797642          DOI: 10.1093/jac/dkt225

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  16 in total

1.  Expression profiles of 50 xenobiotic transporter genes in humans and pre-clinical species: a resource for investigations into drug disposition.

Authors:  K Bleasby; J C Castle; C J Roberts; C Cheng; W J Bailey; J F Sina; A V Kulkarni; M J Hafey; R Evers; J M Johnson; R G Ulrich; J G Slatter
Journal:  Xenobiotica       Date:  2006 Oct-Nov       Impact factor: 1.908

Review 2.  Scientific perspectives on drug transporters and their role in drug interactions.

Authors:  Lei Zhang; John M Strong; Wei Qiu; Lawrence J Lesko; Shiew-Mei Huang
Journal:  Mol Pharm       Date:  2006 Jan-Feb       Impact factor: 4.939

3.  Modulation of human BCRP (ABCG2) activity by anti-HIV drugs.

Authors:  Johanna Weiss; Johanna Rose; Caroline Henrike Storch; Nahal Ketabi-Kiyanvash; Alexandra Sauer; Walter Emil Haefeli; Thomas Efferth
Journal:  J Antimicrob Chemother       Date:  2007-01-03       Impact factor: 5.790

4.  Once-daily dosing of nevirapine in HAART.

Authors:  Bonaventura Clotet
Journal:  J Antimicrob Chemother       Date:  2007-11-14       Impact factor: 5.790

5.  Combination antiretroviral therapy with tenofovir, emtricitabine or lamivudine, and nevirapine.

Authors:  Robert R Redfield; J Scott Morrow
Journal:  Clin Infect Dis       Date:  2008-10-01       Impact factor: 9.079

6.  Inhibition of MRP1/ABCC1, MRP2/ABCC2, and MRP3/ABCC3 by nucleoside, nucleotide, and non-nucleoside reverse transcriptase inhibitors.

Authors:  Johanna Weiss; Dirk Theile; Nahal Ketabi-Kiyanvash; Heike Lindenmaier; Walter Emil Haefeli
Journal:  Drug Metab Dispos       Date:  2006-12-15       Impact factor: 3.922

7.  Renal transport of adefovir, cidofovir, and tenofovir by SLC22A family members (hOAT1, hOAT3, and hOCT2).

Authors:  Yuichi Uwai; Hiroki Ida; Yoshie Tsuji; Toshiya Katsura; Ken-Ichi Inui
Journal:  Pharm Res       Date:  2007-02-15       Impact factor: 4.200

8.  Genetic variants of ABCC10, a novel tenofovir transporter, are associated with kidney tubular dysfunction.

Authors:  Sudeep P Pushpakom; Neill J Liptrott; Sonia Rodríguez-Nóvoa; Pablo Labarga; Vincent Soriano; Marta Albalater; Elizabeth Hopper-Borge; Stefano Bonora; Giovanni Di Perri; David J Back; Saye Khoo; Munir Pirmohamed; Andrew Owen
Journal:  J Infect Dis       Date:  2011-07-01       Impact factor: 5.226

9.  Association of ABCC10 polymorphisms with nevirapine plasma concentrations in the German Competence Network for HIV/AIDS.

Authors:  Neill J Liptrott; Sudeep Pushpakom; Christoph Wyen; Gerd Fätkenheuer; Christian Hoffmann; Stefan Mauss; Heribert Knechten; Norbert H Brockmeyer; Elizabeth Hopper-Borge; Marco Siccardi; David J Back; Saye H Khoo; Munir Pirmohamed; Andrew Owen
Journal:  Pharmacogenet Genomics       Date:  2012-01       Impact factor: 2.089

10.  Localization of the human breast cancer resistance protein (BCRP/ABCG2) in lipid rafts/caveolae and modulation of its activity by cholesterol in vitro.

Authors:  Caroline Henrike Storch; Robert Ehehalt; Walter Emil Haefeli; Johanna Weiss
Journal:  J Pharmacol Exp Ther       Date:  2007-07-24       Impact factor: 4.030

View more
  2 in total

1.  Linking the population pharmacokinetics of tenofovir and its metabolites with its cellular uptake and metabolism.

Authors:  K Madrasi; R N Burns; C W Hendrix; M J Fossler; A Chaturvedula
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2014-11-12

2.  Superior Effectiveness of Zidovudine Compared With Tenofovir When Combined With Nevirapine-based Antiretroviral Therapy in a Large Nigerian Cohort.

Authors:  Kimberly K Scarsi; Geoffrey Eisen; Kristin M Darin; Seema T Meloni; Holly E Rawizza; Eric J Tchetgen Tchetgen; Oche O Agbaji; Daniel I Onwujekwe; Wadzani Gashau; Reuben Nkado; Prosper Okonkwo; Robert L Murphy; Phyllis J Kanki
Journal:  Clin Infect Dis       Date:  2015-11-10       Impact factor: 9.079

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.